Skip to main content

Table 3 Effect of cisplatin (CP) and different treatments of AHE on Phase I antioxidant enzymes

From: Modulatory influence of Acacia hydaspica R. Parker ethyl acetate extract against cisplatin inveigled hepatic injury and dyslipidemia in rats

Group

POD (U/min)

SOD (U/mg protein)

CAT (U/min)

QR (nM/min/mg protein)

Control

13.40 ± 0.23b

1.55 ± 0.06b

24.02 ± 0.08 b

104.8 ± 1.01b

CP

7.23 ± 0.39a

0.39 ± 0.03a

12.80 ± 0.05 a

67.8 ± 0.88 a

AHE alone

13.09 ± 0.27b

1.55 ± 0.08b

24.03 ± 0.03 b

104.7 ± 1.07 b

CP + AHE

9.21 ± 0.29ab*,d

1.08 ± 0.05a, b

14.70 ± 0.06 a, b, d

82.2 ± 0.89 a, b,d

AHE + CP

12.50 ± 0.66b, c**

1.30 ± 0.03a*, b

20.37 ± 0.08 a, b, c

95.3 ± 0.65 a, b, c

CP + Sily

12.57 ± 0.44b

1.31 ± 0.04a*, b

20.66 ± 0.04 ab

95.9 ± 1.26 a,b

  1. Values expressed as mean ± SEM
  2. a Significance at p < 0.0001 Vs. control group
  3. b Significance at p < 0.0001 Vs. Cisplatin (CP) group
  4. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
  5. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
  6. *,** Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)